Clinical Trials Browser

Terminated × Lymphoma, Follicular × pembrolizumab × Clear all

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Phase 2 Terminated

18 enrolled 14 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

159 enrolled

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT02501473 2020-09-09

MK-3475-174

Phase 1/2 Terminated

52 enrolled 23 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Clinical Trials

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Safety Study of SEA-CD40 in Cancer Patients

MK-3475-174